3SBio, Inc. ( (TRSBF) ) has released its Q2 earnings. Here is a breakdown of the information 3SBio, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
3SBio, Inc., a leading biotechnology company based in the Cayman Islands, specializes in the development, production, and sale of biopharmaceutical products, primarily serving the healthcare sector in Mainland China. The company is recognized for its innovative products, including TPIAO, the only commercialized recombinant human thrombopoietin worldwide.
In its interim financial report for the first half of 2025, 3SBio reported a slight decline in revenue by 0.8% to RMB4,355.5 million compared to the same period in 2024. Despite this, the company saw a significant increase in net profit attributable to owners of the parent, which rose by 24.6% to RMB1,358.2 million.
Key financial metrics highlighted in the report include a decrease in gross profit by 2.1% to RMB3,715.8 million, while EBITDA increased by 11.6% to RMB1,832.5 million. The company also noted strategic developments, such as a licensing agreement with Pfizer for its PD-1/VEGF bispecific antibody, which could potentially bring in significant milestone payments.
Looking ahead, 3SBio’s management remains optimistic about the company’s growth prospects, focusing on expanding its product pipeline and leveraging strategic partnerships to enhance its market position in the biopharmaceutical industry.